Patents by Inventor Christopher John Burns
Christopher John Burns has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8486941Abstract: The present invention relates to phenyl amino pyrimidine compounds which are inhibitors of protein kinases including JAK kinases. In particular the compounds are selective for JAK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.Type: GrantFiled: March 12, 2008Date of Patent: July 16, 2013Assignee: YM Biosciences Australia Pty LtdInventors: Christopher John Burns, Andrew Craig Donohue, John Thomas Feutrill, Thao Lien Thi Nguyen, Andrew Frederick Wilks, Jun Zeng
-
Patent number: 8461161Abstract: Compunds of the general formula wherein each of Z1-Z4 is N or CR1 wherein only two of said Z1-Z4 may be N are useful as kinase inhibitors.Type: GrantFiled: November 15, 2007Date of Patent: June 11, 2013Assignee: YM Biosciences Australia Pty LtdInventors: Christopher John Burns, Michael Francis Harte, James T. Palmer
-
Patent number: 8394806Abstract: Compounds of general formula (I), (II), (III) and (V) are described for use in modulating microtubule polymerisation and in the treatment of associated disease states. Use of compounds (I), (III) and (V) in the treatment of kinase-associated disease states is also described. Further described are novel compounds of formula (II), (III) and (V).Type: GrantFiled: July 14, 2011Date of Patent: March 12, 2013Assignee: YM Biosciences Australia Pty LtdInventors: Christopher John Burns, Andrew Frederick Wilks, Michael Francis Harte, Harrison Sikanyika, Emmanuelle Fantino
-
Patent number: 8354408Abstract: The present invention relates to N-containing heterocyclic compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2, JAK3 or TYK2 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.Type: GrantFiled: November 14, 2008Date of Patent: January 15, 2013Assignee: YM Biosciences Australia Pty LtdInventors: David Gerard Bourke, Christopher John Burns, Anthony Nicholas Cuzzupe, John Thomas Feutrill, Marcel Robert Kling, Tracy Leah Nero
-
Patent number: 8329737Abstract: A compound of the general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein A represents a variety of six membered nitrogen containing heterocyclic rings, Q is a bond, halogen, C1-4 alkyl, O, S, SO2, CO or CS and X1, X2, X3 and X4 are optionally substituted by 9 specific substituents or one can be nitrogen. Compositions comprising a carrier and at least one compound of formula (I) are also provided. Further provided are methods of treating tyrosine kinase-associated disease states by administering a compound of formula (I) and methods of suppressing the immune system of a subject by administering a compound of formula (I).Type: GrantFiled: September 30, 2010Date of Patent: December 11, 2012Assignee: YM Biosciences Australia PTY LtdInventors: Michelle Leanne Styles, Jun Zeng, Herbert Rudolf Treutlein, Andrew Frederick Wilks, Marcel Robert Kling, Xianyong Bu, Christopher John Burns
-
Patent number: 8084456Abstract: A compound of general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating a hyperproliferation-related disease state or disorder in a subject using a compound of formula (I) is also described.Type: GrantFiled: December 11, 2003Date of Patent: December 27, 2011Assignee: YM Biosciences Australia Pty LtdInventors: Christopher John Burns, Andrew Frederick Wilks, Xianyong Bu, Harrison Sikanyika, Michael Francis Harte
-
Publication number: 20110269760Abstract: Compounds of general formula (I), (II), (III) and (V) are described for use in modulating microtubule polymerisation and in the treatment of associated disease states. Use of compounds (I), (III) and (V) in the treatment of kinase-associated disease states is also described. Further described are novel compounds of formula (II), (III) and (V).Type: ApplicationFiled: July 14, 2011Publication date: November 3, 2011Applicant: Cytopia Research Pty LtdInventors: Christopher John Burns, Andrew Frederick Wilks, Michael Francis Harte, Harrison Sikanyika, Emmanuelle Fantino
-
Patent number: 8030336Abstract: A compound of the general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating tyrosine kinase-associated disease states in a subject using a compound of formula (I) is also described.Type: GrantFiled: December 15, 2003Date of Patent: October 4, 2011Assignee: YM Biosciences Australia Pty LtdInventors: Christopher John Burns, Marcel Robert Kling
-
Patent number: 7981900Abstract: Compounds of general formula (I), (II) (III) and (V) are described for use in modulating microtubule polymerisation and in the treatment of associated disease states. Use of compounds (I), (III) and (V) in the treatment of kinase-associated disease states is also described. Further described are novel compounds of formula (II), (III) and (V).Type: GrantFiled: December 3, 2004Date of Patent: July 19, 2011Assignee: YM Biosciences Australia Pty LtdInventors: Christopher John Burns, Andrew Frederick Wilks, Michael Francis Harte, Harrison Sikanyika, Emmanuelle Fantino
-
Publication number: 20110092499Abstract: The present invention relates to N-containing heterocyclic compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2, JAK3 or TYK2 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.Type: ApplicationFiled: November 14, 2008Publication date: April 21, 2011Applicant: YM BIOSCIENCES AUSTRALIA PTY LTDInventors: David Gerard Bourke, Christopher John Burns, Antony Nicholas Cuzzupe, John Thomas Feutrill, Marcel Robert Kling, Tracy Leah Nero
-
Publication number: 20110082142Abstract: A compound of the general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein A represents a variety of six membered nitrogen containing heterocyclic rings, Q is a bond, halogen, C1-4 alkyl, O, S, SO2, CO or CS and X1, X2, X3 and X4 are optionally substituted by 9 specific substituents or one can be nitrogen. Compositions comprising a carrier and at least one compound of formula (I) are also provided. Further provided are methods of treating tyrosine kinase-associated disease states by administering a compound of formula (I) and methods of suppressing the immune system of a subject by administering a compound of formula (I).Type: ApplicationFiled: September 30, 2010Publication date: April 7, 2011Inventors: MICHELLE LEANNE STYLES, JUN ZENG, HERBERT RUDOLF TREUTLEIN, ANDREW FREDERICK WILKS, MARCEL ROBERT KLING, XIANYONG BU, CHRISTOPHER JOHN BURNS
-
Publication number: 20100239631Abstract: The present invention relates to thiopyrimidine-based compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2 or JAK3 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases and vascular diseases.Type: ApplicationFiled: January 31, 2008Publication date: September 23, 2010Inventors: David Gerard Bourke, Xianyong Bu, Christopher John Burns, Anthony Nicholas Cuzzupe, John Thomas Feutrill, Tracy Leah Nero, Beata Maria Blannin, Jun Zeng, Shaun Patrick Gaynor
-
Publication number: 20100197671Abstract: The present invention relates to phenyl amino pyrimidine compounds which are inhibitors of protein kinases including JAK kinases. In particular the compounds are selective for JAK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.Type: ApplicationFiled: March 12, 2008Publication date: August 5, 2010Inventors: Christopher John Burns, Andrew Craig Donohue, John Thomas Feutrill, Thao Lien Thi Nguyen, Andrew Frederick Wilks, Jun Zeng
-
Patent number: 7737143Abstract: A compound of general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating kinase-associated disease states using the compound of formula (I) is also described.Type: GrantFiled: December 3, 2004Date of Patent: June 15, 2010Assignee: YM Biosciences Australia Pty LtdInventors: Christopher John Burns, Andrew Frederick Wilks, Xianyong Bu
-
Publication number: 20100130447Abstract: The present invention relates to pyridines or pyrazines that inhibit kinases. In particular the compounds of the invention inhibit members of the class III PTK receptor family such as FMS (CSF-IR), c-KIT, PDGFR?, PDGFR? or FLT3 and KDR, SRC, EphA2, EphA3, EphA8, FLT1, FLT4, HCK, LCK, PTK5 (FRK), SYK, DDR1 and DDR2 and RET. The compounds of the invention are useful in the treatment of kinase associated diseases such as immunological and inflammatory diseases; hyperproliferative diseases including cancer and diseases involving neo-angiogenesis; renal and kidney diseases; bone remodeling diseases; metabolic diseases; and vascular diseases.Type: ApplicationFiled: November 15, 2007Publication date: May 27, 2010Inventors: Christopher John Burns, Michael Francis Harte, James T. Palmer
-
Publication number: 20090281119Abstract: The present invention provides an acid addition salt of N-ethyl-N?-[2-methoxy-4-(5-methyl-4-{[(1S)-1-pyridin-3-ylbutyl]amino}pyrimidin-2-yl)phenyl]urea and uses thereof including a method for the treatment of a hyperproliferation-related disorder. The present invention also provides a pharmaceutical composition comprising an acid addition salt of N-ethyl-N?-[2-methoxy-4-(5-methyl-4-{[(1S)-1-pyridin-3-ylbutyl]amino}pyrimidin-2-yl)phenyl]urea.Type: ApplicationFiled: June 15, 2006Publication date: November 12, 2009Applicant: Cytopia Research Pty Ltd.Inventors: Christopher John Burns, Michael Francis Harte
-
Patent number: 7598272Abstract: A compound of the general formula: or pharmaceutically acceptable salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating protein kinase-associated disease states using the compound of formula I is also described.Type: GrantFiled: April 4, 2006Date of Patent: October 6, 2009Assignee: Cytopia Research Pty LtdInventors: Christopher John Burns, Xianyong Bu, Andrew Frederick Wilks
-
Patent number: 7593820Abstract: The present invention relates to X-ray crystallography studies of a human Janus Kinase 2 (JAK2) domain. More particularly, it relates to the crystal structure of a JAK2 kinase domain bound to a inhibitor. The invention further relates to the use of the crystal and related structural information to select and screen for compounds that interact with JAK2 and related proteins and to compounds that could be used for the treatment of diseases mediated by inappropriate JAK2 activity.Type: GrantFiled: October 11, 2005Date of Patent: September 22, 2009Assignee: Cytopia Research Pty LtdInventors: Andrew Frederick Wilks, Christopher John Burns, Emmanuelle Fantino, Isabelle Lucet, Jamie Rossjohn, Michelle Leanne Styles
-
Patent number: 7511047Abstract: A compound of the general formula: or pharmaceutically acceptable salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating protein kinase-associated disease states using the compound of formula I is also described.Type: GrantFiled: April 4, 2006Date of Patent: March 31, 2009Assignee: Cytopia Research Pty LtdInventors: Christopher John Burns, Xianyong Bu, Andrew Frederick Wilks
-
Publication number: 20080207613Abstract: A compound of the general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein A represents a variety of six membered nitrogen containing heterocyclic rings, Q is a bond, halogen, C1-4 alkyl, O, S, SO2, CO or CS and X1, X2, X3 and X4 are optionally substituted by 9 specific substituents or one can be nitrogen. Compositions comprising a carrier and at least one compound of formula (I) are also provided. Further provided are methods of treating tyrosine kinase-associated disease states by administering a compound of formula (I) and methods of suppressing the immune system of a subject by administering a compound of formula (I).Type: ApplicationFiled: January 12, 2005Publication date: August 28, 2008Applicant: CYTOPIA RESEARCH PTY LTDInventors: Michelle Leanne Styles, Jun Zeng, Herbert Rudolf Treutlein, Andrew Frederick Wilks, Marcel Robert Kling, Christopher John Burns, Xianyong Bu